文献速递血脂与心血管预防

他汀治疗升高脂蛋白(a)水平:一项受试者水平荟萃分析

Statin therapy increases lipoprotein(a) levels.
PubMed 文献 · Eur Heart J · 2020-01-01

该受试者水平荟萃分析纳入6项随机试验共5256例患者,比较他汀与安慰剂及他汀间对Lp(a)的影响。他汀 vs 安慰剂汇总分析几何均值比为1.11(95%CI 1.07-1.14,P<0.0001),他汀组Lp(a)较基线平均百分比变化为8.5%至19.6%。他汀 vs 他汀汇总分析阿托伐他汀 vs 普伐他汀几何均值比为1.09(95%CI 1.05-1.14,P<0.0001)。

要点

  • 他汀治疗可显著升高血浆Lp(a)水平,几何均值比较支持该结论。
  • 他汀组Lp(a)较基线平均升高8.5%–19.6%,安慰剂组为-0.4%至-2.3%。
  • 他汀治疗后Lp(a)升高对残余心血管风险的影响有待进一步研究。

核心结论

  • 他汀治疗显著升高血浆Lp(a)水平,他汀后Lp(a)升高对残余心血管风险的影响需研究。

研究设计与样本

  • 受试者水平荟萃分析,纳入6项随机试验共5256例患者(安慰剂1371例,他汀3885例),含3项他汀 vs 安慰剂和3项他汀 vs 他汀试验,治疗4-104周。
  • 他汀包括阿托伐他汀10 mg/日和80 mg/日、普伐他汀40 mg/日、瑞舒伐他汀40 mg/日、匹伐他汀2 mg/日,Lp(a)用同一验证方法测定。

主要发现

  • 他汀 vs 安慰剂汇总分析中,他汀对安慰剂几何均值比为1.11(95%CI 1.07-1.14,P<0.0001)。
  • 他汀组Lp(a)较基线平均百分比变化为8.5%至19.6%,安慰剂组为-0.4%至-2.3%。
  • 他汀 vs 他汀汇总分析中,阿托伐他汀对普伐他汀几何均值比为1.09(95%CI 1.05-1.14,P<0.0001)。
  • 普伐他汀组Lp(a)较基线平均百分比变化为11.6%至20.4%,阿托伐他汀组为18.7%至24.2%。
  • HepG2肝细胞与阿托伐他汀孵育后LPA mRNA和载脂蛋白(a)蛋白表达增加。

临床怎么用

  • 临床解读他汀治疗后的Lp(a)水平时,需考虑他汀可能升高Lp(a)这一效应。
  • 对他汀治疗后Lp(a)升高的患者,应关注其残余心血管风险并进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Lipoprotein(a) [Lp(a)] is elevated in 20-30% of people. This study aimed to assess the effect of statins on Lp(a) levels. METHODS AND RESULTS: This subject-level meta-analysis includes 5256 patients (1371 on placebo and 3885 on statin) from six randomized trials, three statin-vs.-placebo trials, and three statin-vs.-statin trials, with pre- and on-treatment (4-104 weeks) Lp(a) levels. Statins included atorvastatin 10 mg/day and 80 mg/day, pravastatin 40 mg/day, rosuvastatin 40 mg/day, and pitavastatin 2 mg/day. Lipoprotein(a) levels were measured with the same validated assay. The primary analysis of Lp(a) is based on the log-transformed data. In the statin-vs.-placebo pooled analysis, the ratio of geometric means [95% confidence interval (CI)] for statin to placebo is 1.11 (1.07-1.14) (P < 0.0001), with ratio >1 indicating a higher increase in Lp(a) from baseline in statin vs. placebo. The mean percent change from baseline ranged from 8.5% to 19.6% in the statin groups and -0.4% to -2.3% in the placebo groups. In the statin-vs.-statin pooled analysis, the ratio of geometric means (95% CI) for atorvastatin to pravastatin is 1.09 (1.05-1.14) (P < 0.0001). The mean percent change from baseline ranged from 11.6% to 20.4% in the pravastatin group and 18.7% to 24.2% in the atorvastatin group. Incubation of HepG2 hepatocytes with atorvastatin showed an increase in expression of LPA mRNA and apolipoprotein(a) protein. CONCLUSION: This meta-analysis reveals that statins significantly increase plasma Lp(a) levels. Elevations of Lp(a) post-statin therapy should be studied for effects on residual cardiovascular risk.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Tsimikas S, Gordts PLSM, Nora C, et al. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020. PMID: 31111151. doi:10.1093/eurheartj/ehz310

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。